❌

Reading view

↗️

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

βœ‡Nature Medicine
By: Lars H. Lund Β· Carolyn S. P. Lam Β· Patricia Ely Pizzato Β· Erik MichaΓ«lsson Β· Andrea Mattsson Β· Hans Ericsson Β· Malin Aurell Β· Anna Collen Β· Monika Trebski Β· Carl Whatling Β· Niklas Bergh Β· Andrea L. Vavere Β· Robin Johannes Gerardus Hartman Β· Alain Cohen-Solal Β· Chern-En Chiang Β· Grzegorz Drelich Β· Assen Goudev Β· Martin Hudec Β· Stefan Janssens Β· Jose Francisco Kerr Saraiva Β· Lars KΓΈber Β· Bela Merkely Β· Lisa Mielniczuk Β· Ondrej Toman Β· Sandra Sanders-van Wijk Β· Stephan Baldus Β· Sanjiv J. Shah

Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04615-z

In a phase 2 randomized clinical trial, treatment with the myeloperoxidase (MPO) inhibitor mitiperstat, intended to target the neutrophil–MPO inflammatory pathway, did not improve symptoms or exercise function in individuals with heart failure with preserved or mildly reduced ejection fraction.
  •  
  • ↗️
There are no more articles
❌